Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Genomic Health and Argonaut Manufacturing Services

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, Genomic Health reported a $3.2 million realized gain in 2016 from a sale of equity securities in connection with the sale of a portion of its Invitae stock holdings. The company further sold all its remaining shares in Invitae in January 2017 for $10.2 million, resulting in a realized gain of $2.8 million.

Argonaut Manufacturing Services, a contract manufacturing organization for the life science and molecular diagnostics markets, announced that it has received ISO 13485:2016 certification from the British Standards Institute.

The company also said this week that it has received a $5 million credit facility from Pacific Western Bank division Square 1 Bank. Argonaut will use the proceeds to support capital expenditures associated with its recent expansion.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.